Education
About Us
Working with TipRanks
Follow Us
Candel Therapeutics (CADL)
NASDAQ:CADL
CADL Stock Chart & Stats
$5.74
$0.00(0.00%)
At close: 4:00 PM EST
$5.74
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.25 - $13.68
Previous CloseN/A
Volume524.53K
Average Volume (3M)650.02K
Market Cap
$334.88M
Enterprise Value$244.82M
Total Cash (Recent Filing)$86.96M
Total Debt (Recent Filing)$6.23M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Mar 26, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding54,898,304
10 Day Avg. Volume788,013
30 Day Avg. Volume650,019
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)4.15
Price to Sales (P/S)0.00
P/FCF Ratio-10.17
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-264.10
Enterprise Value/Ebitda-11.80
Forecast
1Y Price Target
$19.00Price Target Upside231.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data & UptakePhase 3 results showing about a 30% reduction in disease recurrence in intermediate-to-high-risk localized prostate cancer, together with strong KOL and physician feedback and supportive survival signals in other tumor types, should bolster clinician adoption and guideline consideration.
ManufacturingManufacturing for CAN-2409 has been scaled toward commercial volumes with viral and cell banks established and ongoing process performance qualification and comparability testing, addressing key CMC hurdles required for approval and launch readiness.
RegulatoryFDA alignment on comparability analysis and use of an SPA-supported disease-free survival endpoint eliminates the need for additional bridging studies and creates a clearer pathway for a biologics license application for CAN-2409, with a BLA submission planned for the fourth quarter of 2026.
Bears Say
Clinical Safety & Market PositioningThe link between androgen deprivation therapy and higher rates of major cardiovascular events could complicate payer decisions and clinical positioning, creating uncertainty around comparative adoption dynamics even as CAN-2409 aims to avoid ADT.
FinancingThe recent debt arrangement with Trinity Capital provides near-term support but analysts expect additional financing will be required in coming years, introducing dilution risk and potential pressure on program timelines.
Pipeline PrioritizationPausing CAN-2409 development in borderline resectable pancreatic cancer reduces near-term pipeline optionality and may delay realization of value from an earlier encouraging phase two survival signal.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics’s price range in the past 12 months?
Candel Therapeutics lowest stock price was $4.25 and its highest was $13.68 in the past 12 months.
What is Candel Therapeutics’s market cap?
Candel Therapeutics’s market cap is $334.88M.
When is Candel Therapeutics’s upcoming earnings report date?
Candel Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 55 days.
How were Candel Therapeutics’s earnings last quarter?
Candel Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.025.
Is Candel Therapeutics overvalued?
According to Wall Street analysts Candel Therapeutics’s price is currently Undervalued.
Does Candel Therapeutics pay dividends?
Candel Therapeutics does not currently pay dividends.
What is Candel Therapeutics’s EPS estimate?
Candel Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Candel Therapeutics have?
Candel Therapeutics has 54,898,304 shares outstanding.
What happened to Candel Therapeutics’s price movement after its last earnings report?
Candel Therapeutics reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -6.301%.
Which hedge fund is a major shareholder of Candel Therapeutics?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.00 (231.01% Upside)
$19.00 (231.01% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 353.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.32%
12-Months-Change
Fundamentals
Return on Equity
-70.17%
Trailing 12-Months
Asset Growth
335.00%
Trailing 12-Months
Company Description
Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$19.00
▲(231.01% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
19.77% Insiders
18.03% Mutual Funds
10.30% Other Institutional Investors
44.75% Public Companies and
Individual Investors